ET Unwired: Reimagining Business | Webinars, Masterclass & WorkshopET Unwired: Reimagining Business | Webinars, Masterclass & Workshop
  • About Us
  • Prive
  • Webinars
    • Upcoming Webinars
    • Past UnWired Sessions
  • Masterclass
  • Roundtables
  • Contact

AMPLIFY PHARMA: Talking Atma Nirbhar

unwiredcp2021-03-18T06:21:04+00:00

Response, Recover and Thrive have been around for a while. Not only as individuals we are strengthening ourselves for a new normal comeback, but the trend is across nations and industries. Pharmaceuticals is among one of those sectors in the throes of big change. With the start of Covid 19 to the day today, the world has been rolling through the stages of response, recovery, thriving and mitigating. Now The question comes HOW DO WE AMPLIFY PHARMA TO MAKE IT STRONGER and ATMA NIRBHAR?

The pharma sector is key to India’s economic progress and despite pressure due to COVID-19, terrorist problem and threat of war from China, India has proven its strength. As per World Bank projections, India will be performing at 3.2 per cent, so it becomes imperative to ensure its self-reliance in APIs, KSMs and intermediates as the need of the hour.

We all understand the kind of pressure pharma industry is facing across the country with demands to deliver innovative lifesaving drugs, vaccines, treatments and more. What stands them out and make them fit for this challenge? As very well said by the Hon. Minister of Commerce and Industry, Piyush Goyal that the country is recognized as the ‘Pharmacy of the world’, as over 120 countries got some essential medicines, during the last two months of the pandemic. He assures captains of the pharmaceutical industry that the government will fully support the industry in its expansion, diversification and strengthening.

Atma Nirbhar BioPharma Industry

Thirty years ago, the pharmaceutical industry in India used to be non-existent. Now, India has evolved to be a world leader in terms of production of high quality, low cost generic drugs, having an annual growth rate of 14%; which takes India to the path of being Atma Nirbhar!
Talking about Active Pharmaceutical Ingredients (APIs), schemes on promotion of bulk drug parks for financing common infrastructure facilities and production linked incentive schemes for promotion of domestic manufacturing of critical KSMs and drug intermediates in the country have been given a go ahead and anti-dumping investigation process has been expedited. The scheme, open for four months from June 2, will allow investors to propose establishment of greenfield facilities for any of the 53 key drug intermediates and bulk drugs that are hardly manufactured in India today.

“One thing is certain: The current strategy is expected to reduce India’s dependence on other nations and be self-reliant on the production of live saving and critical medicines throughout its production chain.”

About the Virtual Webinar:

Customer expectations and Safety has become the buzzword today for every stakeholder in the BioPharma Industry. All are making their business processes and functions automated and innovative to fuel the financial growth. We see an increasing number of pharmaceutical firms and indeed, medical device companies – are partnering and integrating with technology businesses.

India stands a bright chance of substantial growth and become self-reliant in years to come due to efficacy, quality and affordability. Some of the factors which will contribute are Jan Aushadhi scheme, Ayushman Bharat scheme, increase in the disposable income of individuals, self-medication, awareness of basic medicines among the individuals, free distribution of medicines by the government through their wellness centres are few of the factors which will propel growth in this premium industry.

Now the worry is how do the Indian pharma industries see success with the regulatory barriers to enter other markets?

Many studies and business textbooks cite the pharmaceuticals and drug sector as examples when describing barriers to entry. Most countries have some barriers to the entry of the legal drug sector due to the research and manufacturing startup costs, but the U.S. Food and Drug Administration (FDA) and significant health care regulations make the U.S. a special case.

Talking about Europe, its policies strive to secure a high level of public health and innovation and, at the same time, provide support for a competitive industry that ensures that Europe continues to benefit from new medicines

With the theme “AMPLIFY PHARMA: Talking Atma Nirbhar” the virtual webinar will initiate thought provoking discussions and advocate for policies and practices for business growth in biopharma sector. Through the webinar we intend to understand how the Indian Biopharma can work out the regulatory barriers in USA and EU Market to make the business happen. It is powered by Cytiva and Brought to You by The Economic Times – EDGE.

Discussion Points

1. Bio Pharma operations: The path to recovery and the next normal
2. Increasing interactions between government and bio pharma industry players
3. How can industry stimulate growth drivers to expand the market faster? What are the risks to growth and regulatory barriers and how should these be managed?
4. What is there in Atma Nirbhar campaign to make the BioPharma sector more self-reliant?
5. Towards the path of business Growth – Schemes, policies,


Speakers

Chandrakant Kathote
operations of Biotech
Lupin Limited

Chandrakant Kathote is heading the operations of Biotech site of Lupin Limited as a Site Head. He has more than 22 years of experience in the Biotech Industry during which he worked for companies like Biocon, Panacea and Torrent. During his career he led scale-up and commercialization activities of Biosimilar products for several geographies like US, Japan, Europe, Australia, Canada, Brazil, India and others. He has gained good knowledge on regulatory requirements from his interaction with various regulatory agencies. He played a key role in creating large scale Biotech facilities to support long term commercialization plans.
Close

Francis Van Parys
Vice President Commercial, Asia-Pacific
Cytiva

Francis Van Parys is currently responsible for providing transformational technologies in
biopharmaceutical research, manufacturing and diagnostics to Cytivacustomers and partners in the life sciences industry in China, India, Japan, Korea, ASEAN and Australia-New Zealand.

While his name would suggest a French connection, Francis is a Belgian citizen whose career has spanned
far and wide, and he is currently based in Asia.

Francis is a seasoned global executive who served in a number of General Management roles before becoming President of GE Healthcare Korea in 2017. In that role, he was responsible for helping provide medical technologies and solutions to the healthcare industry in Korea, from diagnostic imaging, monitoring and digital solutions through to life sciences.

He joined Cytivawhen it was known as GE Healthcare Life Sciences in 2009 as General Manager for
Commercial Operations in EMEA and was later appointed Global Product General Manager, Research and Applied Markets, responsible for the consumables and hardware portfolio. He then became Global Commercial General Manager for Cell Culture in 2016.

Francis started his career by joining GE in a sales leadership program in 2001 and had early-career assignments in Belgium and Germany, before taking on sales marketing positions of increasing responsibility at GE Industrial Solutions.

He graduated from the University of Ghent in Belgium with a Master’s degree in Material Science and Engineering. He also holds a Master of Science in Polymer Technology from UMIST in Manchester, UK. Francis lives in Seoul, Korea, with his wife and two sons.

Close

Dr. Himanshu Gadgil
CEO
Enzene

Dr.Jaby Jacob
Senior President – Research & Development

Jaby comes with over 21 years of extensive research experience across organizations in India and the US. He has been instrumental in the development of several biopharmaceutical products including monoclonal antibodies. His work in companies such as Kemwell Biopharma, Dr. Reddy’s and AMGEN, includes the development of biopharmaceutical products including biosimilars, …management of contract development and manufacturing (CDMO) activities. Strategies for biosimilar drug development for regulated as well emerging markets, process characterization, analytical methods development & validation and technology transfer management have been some of his other contributions.
Past Experience

• Vice President, Kemwell Biopharma Pvt. Ltd., India
• Asst. Vice President, Kemwell Biopharma Pvt. Ltd.
• Director, Dr. Reddy’s Laboratories, Biologics Development Center, Hyderabad
• Associate Director, Dr. Reddy’s Laboratories, Biologics Development Center, Hyderabad
• Senior Scientist, Amgen Inc, USA
• Scientist, Advanced Photon Source, Argonne National Laboratory and Illinois Institute of Technology, IL, USA
• Post-doctoral Fellow, Department of Biochemistry and Molecular Biology, University of Chicago and Argonne National Laboratory, Chicago, USA
• Post-doctoral Fellow, Department of Chemical Engineering and Institute for Physical Science and Technology, University of Maryland, College Park, Maryland, USA
• Co-author of 24 peer reviewed scientific publications and 2 patents

Education

• Doctor of Philosophy (Ph. D), Indian Institute of Science, Bangalore
• Master of Science (M. Sc), Indian Institute of Technology, Chennai

Key skills

Biopharmaceuticals development, CDMO management, Drug development, Regulatory strategy

Close

Raghavendra Goud
GM
Cytiva, South Asia

Sandeep Majumdar
Vice President Operations
INTAS Pharmaceuticals

Sandeep Majumdar is presently associated with INTAS Pharmaceuticals Biopharma div. as VP Operations. In his career spanning over 23 yrs he has worked with various companies like Wokhardt, Sartorius, Reliance life sciences, Biocon and Intas. He has a very versatile experience in projects and manufacturing. He has contributed with his technical and strategic inputs for the successful implementation of the multiple projects. Being in highly competitive and knowledge intensive business his core focus have been to learn and evolve. He has always focussed on Intas’s priority of providing affordable and quality biosimilars.
Close

Dr. Sanjay Singh
CEO
Gennova Biopharmaceuticals Ltd.

Dr. Sanjay Singh is the Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious, and affordable biotherapeutics.

As a founder CEO, since 2006, at Gennova, Dr. Singh focused on innovations in bio-manufacturing technologies that culminated in the commercialization of seven life-saving bio-therapeutics in the cardiovascular, neurology, nephrology, and oncology market.

Under his leadership, his team pioneered the work that
led to its approval of tenecteplase for Acute Ischemic Stroke (AIS) — the first time globally, securing global patents. The Department of Biotechnology (DBT), Govt. of India recognized this innovation for the ‘Biotech product, process development and commercialization award 2019’ and it found its way in the list of drugs for emergency care for stroke management in the guideline —‘Prevention and Management of Stroke,’ issued by the Ministry of Health and Family Welfare, Govt. of India.

Under him, Gennova has directed their research to cater to vaccine development of neglected diseases, in particular Malaria, HPV, Leishmaniasis, and Tuberculosis, in partnership with various national and global organizations, including the NIH, US-FDA etc.

Dr. Singh is currently a member of various important committee of national relevance, which notable include the Scientific Advisory Board of the National Center for Cell Sciences (NCCS), Pune, Research Council of the Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, National Committee for Biotechnology- Confederation of Indian Industry (CII), New Delhi. Additionally, he is an invited member of the Indo-US Vaccine Action Program (VAP).

Contributing towards the national interests, Dr. Singh served as a member of the committee for the development of the India Guidelines on Similar Biologics (Regulatory Requirements for Marketing Authorization) constituted by the Department of Biotechnology (DBT), Ministry of Science and Technology (Govt of India) and Central Drugs Standard Control Organization (CDSCO) and Ministry of Health and family welfare (Govt. of India ). Contribution of this committee led to the establishment of a transparent path for successful development (clarity for Biotech Industry) and approval process (clarity of guidelines for regulatory agencies) to market the biosimilar drug product in India.
Dr. Singh holds a Ph.D. degree in Biochemistry from Central Drug Research Institute (CDRI), Lucknow, India. Before joining Gennova, he headed the Antigen Research Section at the Malaria Vaccine Development Unit of the National Institutes of Allergy and Infectious Diseases (NIAID), NIH, USA.

Close

Shyam Pattabiraman
Vice President
Jubilant Bhartia Group

Shyam is CFO at Jubilant Therapeutics, that he helped carve out from the parent company Jubilant Life Sciences and set up as a standalone biotech venture in 2019. Shyam is also involved in other initiatives at Jubilant such as corporate venture investing, digital and innovation.

Earlier he managed the strategy office at a leading India based conglomerate where he helped scale a new business and managed a successful M&A exit valued at over a billion dollars. Prior to Shyam’s industry stints, he spent most of his career as a management consultant at PwC – advising startups and leading global companies in strategy. Shyam has spoken at various conferences and is an active participant in the World Economic Forum community in addition to authoring over fifty thought leadership publications.

He is a graduate of London School of Economics and State University of New York.

Close

Vikash Agarwalla
MD & Partner
Boston Consulting Group

Vikash Agarwalla is an MD & Partner in the Gurgaon office of The Boston Consulting Group.
He has over 15 years of consulting experience. Vikash has worked on a range of business topics including growth strategy, cost reduction, operations excellence and digital transformation across pharmacos in India.
He holds an MBA from IIM Lucknow and BE (Mech.) from Delhi College of Engineering.
Close

Contact Us

  • Address:: Lotus Corporate Park, 19th floor – 1902 and 1901, G – Wing, Off Western Express Highway, Geetanjali Railway Colony, Laxmi Nagar, Goregaon (East), Mumbai – 400063
  • Email:: etunwired@et-edge.com

Recent Webinar

Modernizing Data Management

As organizations realize the benefits of digital and cloud transformation, it has resulted in a further increase in pace... read more

Unlock And Scale

There is no better approach to solving challenges than the famous saying “two heads are better than one. Harnessing the... read more

Innovation stories of India

read more

© Copyright 2020. All Rights Reserved. An ET Edge initiative. Refund Policy | Privacy Policy | Terms of Use | FAQs
  • About Us
  • Prive
  • Webinars
    • Upcoming Webinars
    • Past UnWired Sessions
  • Masterclass
  • Roundtables
  • Contact

Contact Us

  • Address:: Lotus Corporate Park, 19th floor – 1902 and 1901, G – Wing, Off Western Express Highway, Geetanjali Railway Colony, Laxmi Nagar, Goregaon (East), Mumbai – 400063
  • Email:: etunwired@et-edge.com

Recent Webinar

Modernizing Data Management

As organizations realize the benefits of digital and cloud transformation, it has resulted in a further increase in pace... read more

Unlock And Scale

There is no better approach to solving challenges than the famous saying “two heads are better than one. Harnessing the... read more

Innovation stories of India

read more